Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatmentexperienced patients with drugresistant hiv infection: Week 96 results of the benchmrk 1 and 2 phase III trials

Roy T. Steigbigel, David A. Cooper, Hedy Teppler, Joseph J. Eron, Jose M. Gatell, Princy N. Kumar, Jurgen K. Rockstroh, Mauro Schlechter, Christine Katlama, Martin Markowitz, Patrick Yeni, Mona R. Loutfy, Adriano Lazzarin, Jeffrey L. Lennox, Bonaventura Clotet, Jing Zhao, Hong Wan, Rand R. Rhodes, Kim M. Strohmaier, Richard J. BarnardRobin D. Isaacs, Bach Yen T. Nguyen

Research output: Contribution to journalArticleResearchpeer-review

171 Citations (Scopus)

Abstract

BENCHMRK-1 and -2 are ongoing double-blind phase III studies of raltegravir in patients experiencing failure of antiretroviral therapy with triple-class drug-resistant human immunodeficiency virus infection. At week 96 (combined data), raltegravir (400 mg twice daily) plus optimized background therapy was generally well tolerated, with superior and durable antiretroviral and immunological efficacy, compared with optimized background therapy alone. © 2010 by the Infectious Diseases Society of America. All rights reserved.
Original languageEnglish
Pages (from-to)605-612
JournalClinical Infectious Diseases
Volume50
Issue number4
DOIs
Publication statusPublished - 15 Feb 2010

Fingerprint Dive into the research topics of 'Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatmentexperienced patients with drugresistant hiv infection: Week 96 results of the benchmrk 1 and 2 phase III trials'. Together they form a unique fingerprint.

  • Cite this

    Steigbigel, R. T., Cooper, D. A., Teppler, H., Eron, J. J., Gatell, J. M., Kumar, P. N., Rockstroh, J. K., Schlechter, M., Katlama, C., Markowitz, M., Yeni, P., Loutfy, M. R., Lazzarin, A., Lennox, J. L., Clotet, B., Zhao, J., Wan, H., Rhodes, R. R., Strohmaier, K. M., ... Nguyen, B. Y. T. (2010). Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatmentexperienced patients with drugresistant hiv infection: Week 96 results of the benchmrk 1 and 2 phase III trials. Clinical Infectious Diseases, 50(4), 605-612. https://doi.org/10.1086/650002